BIOMAT Database Logo BIOMAT Database Logo

[Conservative therapy of arterial occlusive diseases. Double-blind study on the effect of butalamine hydrochloride]. 1980

H Seboldt

In a double blind placebo-controlled trial the influence of butalamine-hydrochloride (Adrevil forte) in a daily dosage of 3 x 2 tablets on the exercise tolerance of muscles with impaired blood flow in the lower limb was evaluated. The drug was tested versus placebo in a total of 32 patients suffering from peripheral arterial insufficiency stadium II according to Fontaine with occlusions in one or both extremities. Clinical parameters measured were muscle ergometry, plethysmography as well as the assessment of the painfree walking distance. During the whole trial the systemic blood pressure was monitored. The group receiving the active drug showed already after two weeks therapy a statistically significant improvement in the walking distance. After the end of 8 weeks therapy the walking distance in the group under active drug therapy was increased 4 times. Measurements of perfusion also showed significantly higher values under active therapy. The systemic blood pressure was not affected during the 8 weeks therapy with Adrevil forte.

UI MeSH Term Description Entries
D007383 Intermittent Claudication A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE. Claudication, Intermittent
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010069 Oxadiazoles Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms. Oxadiazole
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

H Seboldt
[Therapy of arterial occlusive diseases. The effect of bencyclan in trained patients with peripheral arterial occlusive disease (Double-blind study)].
July 1978, Fortschritte der Medizin,
H Seboldt
[Drug therapy of chronic arterial occlusive diseases of the lower extremities with butalamine-HCl].
May 1979, Fortschritte der Medizin,
H Seboldt
[Modern conservative therapy of arterial occlusive diseases].
August 1980, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
H Seboldt
[Conservative therapy of peripheral arterial occlusive diseases].
January 1993, Zeitschrift fur Kardiologie,
H Seboldt
[Conservative therapy of arterial occlusive diseases on a rational basis].
May 1972, Deutsches medizinisches Journal,
H Seboldt
[Therapy of arterial-circulation disorders in the legs. Muscle-ergometric studies under the effects of butalamine hydrochloride in a double-blind trial].
April 1976, Fortschritte der Medizin,
H Seboldt
[Late results of conservative therapy of arterial occlusive diseases].
January 1983, Verhandlungen der Deutschen Gesellschaft fur Herz- und Kreislaufforschung,
H Seboldt
[Late results of conservative therapy of arterial occlusive diseases].
July 1984, Der Internist,
H Seboldt
[Effectiveness of Dusodril-Pi in arterial occlusive diseases. A multicentric double-blind study].
October 1979, Die Medizinische Welt,
H Seboldt
[Conservative therapy of arterial occlusive disease].
February 1989, Herz,
Copied contents to your clipboard!